About Predigen
Predigen is a company based in United States founded in 2014 by Christopher Woods, Geoffrey Ling, and Ephraim Tsalik was acquired by Biomeme in August 2021. Predigen operates in a competitive market with competitors including Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
- Headquarter United States
- Founders Christopher Woods, Geoffrey Ling, Ephraim Tsalik
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Predigen
Detailed funding history for Predigen
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Predigen
Predigen has secured backing from 1 investor. Prominent investors backing the company include Biomeme.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Smartphone-based DNA detection platform is developed for diagnostics.
|
Locked | Locked | Locked |
Investor details for Predigen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Predigen
Investment portfolio details for Predigen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Predigen
Detailed financials for Predigen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Predigen Comparisons
Peer comparison for Predigen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Predigen
Predigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Parse Biosciences, Biofidelity, RareCyte, Qiagen and RainDance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Products and reagents for molecular diagnostic assays are supplied.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
|
| Locked | Locked | Locked |
Electrophoresis-based in vitro diagnostics products are developed and provided.
|
Detailed competitors of Predigen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Predigen
Complete news archive for Predigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Predigen
Predigen was founded in 2014.
Predigen is headquartered in United States.
Predigen was established in 2014 as a spin-out from Duke University in the United States. Host gene expression signatures are developed by the company for prognostic, diagnostic, and therapeutic monitoring applications. A portfolio of signatures has been created for use in viral, bacterial, and fungal infections, sepsis, cardiovascular disease, radiation exposure, autoimmune and inflammatory conditions, and cancer. Operations are centered on biotechnology for medical diagnostics.
Predigen's top competitors include Neogen, Qiagen and Parse Biosciences.
Predigen has 1 investor. Key investors include Biomeme.